146432-17-9Relevant articles and documents
Asymmetric synthesis of naproxen via a pinacol-type reaction
Brown
, p. 1551 - 1552 (1992)
An asymmetric pinacol-type rearrangement was used in the synthesis of (S)-naproxen. The pinacol-type reaction of a sec-tert vicinal diol provided an α-aryl ketone wich was oxidized with sodium hypochlorite in the presence of methanol to the methyl ester of naproxen.
FORUMLATIONS
-
Page/Page column 5-6, (2009/09/25)
This invention relates to the use of lactamide compounds of formula (I): CH3CH(OH)C(=O)NR1R2, where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl, in formulations to reduce the toxicity associated with other formulation components; to the use of certain lactamide compounds as solvents, especially in formulations, particularly in agrochemical formulations and in environmentally friendly formulations; to novel lactamide compounds; and to processes for preparing lactamide compounds.
STEREOSELECTIVE SYNTHESIS OF 1-[6-ETHYL-1,2-DIHYDROXY-PROPYL)-PYRIDIN-3-YL]-3-[2-(4-METHYL-PIPERAZIN-1-YL)-BENZYL]-PYRROLIDIN-2-ONE
-
Page/Page column 38-39, (2008/12/06)
The present invention is related to the stereospecific preparation of 1-[6-(1- ethyl-1,2-dihydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]- pyrrolidin-2-one, and the intermediates thereof. Another aspect of the invention relates to 1-[6-(1 -ethyl- 1,2-dihydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1- yl)-benzyl]-pyrrolidin-2-one, wherein the carbon atoms having the 1,2-dihydroxy substituents are any of the four diastereomers selected from (R,R), (R,S), (S,R), and (S, S), wherein the carbon three of the pyrrolidin-2-one is (R) or (S), pharmaceutically acceptable salts thereof, solvates thereof, pharmaceutical compositions containing them, and methods using them for in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated.